BCAX.US Bicara Therapeutics Inc. Common Stock

Healthcare Biotechnology USA Stocks
10.02 USD
Close of Nov 14, 2026
7.87 30.99
Market cap
USD 665M
P/E
-
P/B
1.64x
ROE
-59.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BCAX.US undervalued?

Graham number

The Graham number of Bicara Therapeutics Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bicara Therapeutics Inc. Common Stock fundamental analysis

No fundamental analysis for Bicara Therapeutics Inc. Common Stock yet.

Bicara Therapeutics Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Full company profile